ACD-A
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- ACD-A
- Generic name
- ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A
- Manufacturer
- Fenwal, Inc.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- ab19b011-0a51-4f04-9881-d9fc7cae95ae
- SPL ID
- 1b32fa60-df62-4ab3-86ed-db2a262de054
- Version
- 7
- Effective date
- 2025-11-25
- Source export date
- 2026-09-28
- Source partition
- 6
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0006-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/e0861bcde1444ef952820955caafc6f3fd29783e5ade07a13d933aa3336b399f/drug-label-0006-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 05:36:56
| Harmonized routes |
|---|
| INTRAVENOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application number | BN160918 | openfda.application_number | |
| brand name | ACD-A | openfda.brand_name | |
| generic name | ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A | openfda.generic_name | |
| manufacturer name | Fenwal, Inc. | openfda.manufacturer_name | |
| ndc | package | 0942-0641-04 | openfda.package_ndc |
| ndc | product | 0942-0641 | openfda.product_ndc |
| ndc11 | package | 00942064104 | derived:openfda.package_ndc |
| spl id | 1b32fa60-df62-4ab3-86ed-db2a262de054 | id | |
| spl set id | ab19b011-0a51-4f04-9881-d9fc7cae95ae | set_id | |
| unii | 1Q73Q2JULR | openfda.unii | |
| unii | XF417D3PSL | openfda.unii | |
| unii | LX22YL083G | openfda.unii |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.